Prognostic Significance of Serum LDH in B Cell Chronic Lymphoproliferative Disorders: A Single-Institution Study of 829 Cases in China

Abstract Background: B-cell chronic lymphoproliferative disorders (B-CLPD) comprise several indolent lymphoma subtypes with similar characteristics but also difference and heterogeneity. Several prognostic systems had been established for separate subtypes, such as Rai/Binet stage system for CLL, FLIPI for follicular lymphoma. Here, we want to explore the prognostic role of some common clinical characteristics in each lymphoma subtype, such as serum LDH. Materials and methods: The clinical data of 829 patients with B-CLPD including clinical features, LDH expression level, cytogenetic abnormalities and therapeutic outcome were analyzed retrospectively in department of lymphoma & myeloma, Institute of hematology & Blood disease hospital from April 1990 to August 2013, and the prognosis of B-CLPD patients with different expression levels of LDH was compared, including overall survival (OS) and progression-free survival (PFS) rates. Results: 829 patients were divided into three groups, including 426 (51.4%) patients with chronic lymphocytic lymphoma (CLL), 307 (37.0%) patients with non-CLL B-CLPD and 96 (11.6%) patients with BLPD-U. Elevated serum LDH at diagnosis was detected in 112 (26.3%), 85 (27.7%) and 23 (24.9%) of CLL, non-CLL B-CLPD and BLPD-U group, respectively. Patients with elevated LDH B-CLPD had poorer 5-year overall survival rate (CLL: 63.8% vs 83.0%; non-CLL B-CLPD: 62.2% vs 78.1%; BLPD-U: 47.4% vs 88.6%) and 5-year progression-free survival rate (CLL: 52.0% vs 78.2%; non-CLL B-CLPD: 40.8% vs 75.6%; BLPD-U: 48.9% vs 89.5%) than LDH normal patients. Univariate analysis showed that LDH expression, hemoglobin level, platelet count, B symptoms, P53 deletion were prognostic factors for CLL patient survival, while LDH expression, platelet count, albumin level affected non-CLL B-CLPD patient survival significantly and LDH expression, albumin level, ECOG PS scores for BLPD-U patient survival. Multivariate analysis showed that elevated LDH was an independent significant prognostic factor for overall survival (P<.001) and progression-free survival (P<.001) in all three groups. Conclusion s: Based on these data, we conclude that elevated serum LDH at diagnosis is an unfavorable prognostic factor in patients with B-CLPD. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan

Creative Surgery and Oncology ◽

10.24060/2076-3093-2020-10-3-183-189 ◽

2020 ◽

Vol 10 (3) ◽

pp. 183-189

Author(s):

Sh. Kh. Gantsev ◽

O. N. Lipatov ◽

K. V. Menshikov ◽

D. S. Tursumetov ◽

Kh. S. Saydulaeva

Keyword(s):

Overall Survival ◽

Chronic Hepatitis ◽

Survival Rate ◽

Survival Rates ◽

Elevated Serum ◽

Malignant Neoplasm ◽

Progression Free Survival ◽

Control Group ◽

Overall Survival Rate ◽

Free Survival

Introduction. Hepatocellular carcinoma (HCC) is the most common primary malignant neoplasm of the liver. During the early stages, HCC is asymptomatic, which makes X-ray examination a particularly important diagnostic tool. According to WHO data, the mortality rate from HCC was 782,000 in 2018. HCC is associated with a number of risk factors: a high viral load, liver cirrhosis, detected HBeAg and elevated serum HBsAg levels. Inhibitors of tyrosine kinase receptors increase the overall survival and progression-free survival rates in patients with metastatic HCC. In this article, we conduct an analysis of results of the REFLECT study obtained for Russian patients by the Republican Clinical Oncological Dispensary, Ufa.Materials and methods. The experimental group included 9 patients (52.9%) receiving Lenvatinib. The control group included 8 patients (47.1%)) underwent therapy with Sorafenib at a dose of 800 mg per day 7 (41.17%) patients had a history of chronic hepatitis, of which hepatitis B and chronic hepatitis C was confirmed in 6 and 1 cases, respectively.Results and discussion. Over the period from 2017 up to the present, progression-free survival was observed in three patients (17.6%), of which 2 and 1 received Lenvatinib and Sorafenib, respectively. Overall survival was 10.5 months. The median overall survival rate in the experimental and control groups was 9.8 and 11.2 months, respectively. These parameters are considered comparable, provided that the sample was small.Conclusions. The use of Lenvatinib demonstrated the efficacy comparable to that of Sorafenib in terms of the overall survival rate in patients with inoperable HCC. Lenvatinib allowed statistically and clinically significant improvement in the progression-free survival and time to progression to be achieved.

Download Full-text

Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study

Cancers ◽

10.3390/cancers12041013 ◽

2020 ◽

Vol 12 (4) ◽

pp. 1013

Author(s):

Chara Papadaki ◽

Stavroula Manolakou ◽

Eleni Lagoudaki ◽

Spyros Pontikakis ◽

Despo Ierodiakonou ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Prognostic Factor ◽

Protein Expression ◽

Epithelial Ovarian Cancer ◽

Cancer Cells ◽

Progression Free Survival ◽

Free Survival ◽

Protein Levels ◽

Low Expression

CD44, a surface marker for cancer stem cells, interacts with PKM2, a key regulator of aerobic glycolysis, and enhances the glycolytic phenotype of cancer cells leading to antioxidant protection and macromolecules’ synthesis. To clarify the clinical importance of this “cross-talk” as a mechanism of drug resistance, we assessed the expression both of PKM2 and of CD44 in cancer cells of patients with epithelial ovarian cancer (EOC) treated with platinum-based treatment. One hundred and seventy-one patients with EOC were assessed for PKM2mRNA expression and PKM2 and CD44 proteins detection. Associations with progression-free survival (PFS) and overall survival (OS) were assessed with Kaplan–Meier and adjusted Cox regression models. PKM2mRNA and protein as well as CD44 protein were detectable in the majority of patients. Positive correlation between PKM2 and CD44 protein expression was observed (Spearman rho = 0.2, p = 0.015). When we used the median to group patients into high versus low expression, high PKM2mRNA and protein levels were significantly associated with lower progression-free survival (PFS; p = 0.003 and p = 0.002, respectively) and shorter overall survival (OS; p ≤ 0.001 and p = 0.001, respectively). However, high CD44 protein expression was significantly correlated only with shorter OS (p = 0.004). Moreover, patients with both high PKM2 and CD44 protein levels experienced shorter PFS and OS (p = 0.007 and p = 0.003, respectively) compared to patients with low expression of both proteins. Finally, higher PKM2mRNA and protein expression as well as CD44 protein expression (HR: 2.16; HR: 1.82; HR: 1.01, respectively) were independent prognostic factors for decreased median OS (mOS), whereas only PKM2 protein expression (HR: 1.95) was an independent prognostic factor for decreased median PFS (mPFS). In conclusion, PKM2 expression is a negative prognostic factor in EOC patients, but the interaction between CD44 and PKM2 that may be implicated in EOC platinum-resistance needs further investigation.

Download Full-text

p63 expression is a prognostic factor in colorectal cancer

The International Journal of Biological Markers ◽

10.5301/jbm.2012.9581 ◽

2012 ◽

Vol 27 (3) ◽

pp. 212-218 ◽

Cited By ~ 3

Author(s):

Hong-Qiang Guo ◽

Guo-Liang Huang ◽

Ou-Fei Liu ◽

Yan-Yan Liu ◽

Zhi-Hua Yao ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Prognostic Factor ◽

Malignant Tumors ◽

Univariate Analysis ◽

Progression Free Survival ◽

Clinicopathological Factors ◽

Invasion And Metastasis ◽

Free Survival ◽

Potential Prognostic Factor

p63 is highly expressed in some malignant tumors and is associated with tumorigenesis, invasion and metastasis. The aim of our study was to evaluate the clinical significance of p63 in colorectal cancer (CRC). p63 expression was detected by immunohistochemistry in 66 CRC patients. Correlations between p63 expression and clinicopathological factors, progression-free survival (PFS) and overall survival (OS) were analyzed. Among the 66 CRC cases, 31 cases (47%) exhibited a high score of p63 expression, while 35 cases (53%) were marked with a low score. The p63 level correlated with peritumoral deposits (p=0.021). The 5-year OS rates in the low p63 score and high p63 score groups were, respectively, 49% and 74% (p<0.001). The 5-year PFS rates in the low p63 score and high p63 score groups were, respectively, 44% and 71% (p<0.001). Univariate analysis revealed that p63 expression was correlated with OS and PFS. Multivariate analysis suggested that p63 expression was an independent prognostic factor for OS (p=0.035). In conclusion, p63 was negatively correlated with peritumoral deposits and positively associated with OS and PFS in CRC. The data suggest that p63 is a potential prognostic factor for CRC.

Download Full-text

Should Albumin Be Considered a Prognostic Factor For Brazilian Patients Diagnosed With Classical Hodgkin Lymphoma

Blood ◽

10.1182/blood.v122.21.5049.5049 ◽

2013 ◽

Vol 122 (21) ◽

pp. 5049-5049

Author(s):

Guilherme Fleury Perini ◽

Egyla M Cavalcante ◽

Joao Garibaldi Rezende ◽

Davimar Miranda Borducchi ◽

Fernanda Cunha Vieira ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factor ◽

Partial Response ◽

Early Stage ◽

Progression Free Survival ◽

Refractory Disease ◽

Advanced Stage ◽

Classical Hodgkin Lymphoma ◽

Free Survival ◽

Stage Disease

Abstract Introduction In 1998, Hasenclever et al published the International Prognostic Factor for patients with advanced stage classical Hodgkin lymphoma (cHL). Since then, the IPS has been considered the most important prognostic score for cHL and has been validated in different populations, and also in early stage cHL. From the seven factors analyzed in the IPS, albumin is the only that can be influenced by environmental, economic and nutritional status. We hypothesized if, in developing countries, albumin should still be a prognostic factor, and if so, what is the ideal cutoff value. Objectives To assess if albumin at diagnosis of cHL patients in Brazil was prognostic for overall survival (OS) and progression free survival (PFS) and what would be the best cutoff. Patient and Methods This is a retrospective multicenter study conducted by the Universidade Federal de São Paulo, São Paulo, Brazil. Only confirmed cases of cHL, diagnosed between April 1996 To January 2013, with clinical, epidemiological and laboratorial parameters available after a thorough chart review were included in this study. Response was defined as complete (CR) or less than CR (partial response or refractory disease). Event was defined as treatment related mortality, progression (defined as time for initiation of salvage therapy) or relapse. Advanced stage disease was defined as stage I or II with B symptoms and/or bulky disease and stage III or IV. Patients with conflicted data or loss of follow up were excluded from the analysis. Results A total of 179 patients were selected for this study. Nodular sclerosis subtype was diagnosed in 125 (68.9%) of all patients. Median age at diagnosis was 28 years old (ranging from 13-76). Only 22.9% of patients presented with early stage disease. ABVD chemotherapy protocol was the initial therapy in 91% of patients. Consolidation radiotherapy was done in 48.6%. Median serum albumin was 3.74 (range: 1.34 – 5.52). Median albumin for patients treated in private hospital was 3.6 (range: 2.7 – 4.7) in contrast to patients treated in public hospitals with a median level of 3.0 (range: 1.34 – 5.52), although this difference was not statistically different. Overall responses were: CR in 90%, Partial response/Refractory disease in 10%; one patient died due to treatment-related toxicity. Overall Survival (OS) for the entire group was 93% in 5 years (CI95% 87-96%), with a progression free survival (PFS) of 79% (CI95% 73-86%). When applying the cutoff of 4g/dL, albumin was not related to OS (91% vs 98%, p=ns) or PFS (85 vs 77%, p=ns). However, an albumin value greater than 2g/dL was related to a better OS (94% vs 71%, p=0.01). Conclusions Prognostic factors may differ from different studied populations. This is particularly truth for albumin, which is the only IPS factor influenced by the environment. In our study, however, albumin was not significantly related to OS or PFS, unless when a cutoff of 2g/dL was used. Disclosures: No relevant conflicts of interest to declare.

Download Full-text

Systemic immune-inflammation index to predict survival in patients with metastatic urothelial carcinoma treated with second-line vinflunine.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e17019 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e17019-e17019

Author(s):

Patrik Palacka ◽

Jana Katolicka ◽

Tana Albertova ◽

Katarina Rejlekova ◽

Jana Obertova ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factor ◽

Urothelial Carcinoma ◽

Progression Free Survival ◽

Second Line ◽

Free Survival ◽

Second Line Chemotherapy ◽

Metastatic Urothelial Carcinoma ◽

Immune Inflammation ◽

Line Chemotherapy

e17019 Background: Based on our previous study, the systemic immune-inflammation index (SII) is a prognostic factor in patients with metastatic urothelial cancer (MUC) treated with platinum-based first-line chemotherapy. The objective of this retrospective analysis was to explore prognostic value of the SII at baseline of second-line chemotherapy with vinflunine in MUC population. Methods: We evaluated 70 consecutive MUC (53 bladder, 21 upper tract) patients (54 men) treated with second-line chemotherapy with vinflunine at four oncological departments since 2010. ECOG performance status (PS) ≤ 1 had 44 patients (pts.), haemoglobin < 10 g/dL was present in 25 pts. and liver involvement in 18 pts. SII was based on platelets (P), neutrophils (N) and lymphocytes (L) counts defined as PxN/L. This study population was dichotomized by median into low SII and high SII groups. Progression-free survival (PFS), overall survival (OS) and their 95% CI were estimated by Kaplan-Meier method and compared with logrank test. Results: At median follow-up of 9.0 months (1-29 months), 68 pts. experienced disease progression and 62 died. Pts. with low SII at baseline had significantly better PFS and OS opposite to those with high SII (HR = 0.61, 95% CI 0.37-1.00, p = 0.0318 for PFS, HR = 0.60, 95% CI 0.36-1.00, p = 0.0312 for OS, respectively). In addition to the prognostic factors by Bellmunt (ECOG PS ≥ 1, liver involvement, haemoglobin < 10 g/dL), we identified peritoneal metastases as a factor associated with significantly worse survival (HR = 0.28, 95% CI 0.11-0.72, p < 0.00001 for PFS, HR = 0.30, 95% CI 0.12-0.75, p < 0.00001 for OS, respectively). Conclusions: The SII at baseline of treatment with second-line vinflunine represents a prognostic factor for pts. with MUC. Based on SII, pts. could be stratified into clinical trials in future. MUC pts. with high SII might be candidates for a different treatment approach. Key Words: Metastatic Urothelial Carcinoma. Systemic Immune-Inflammation Index. Vinflunine. Progression-Free Survival. Overall Survival.

Download Full-text

Loss of Heterozygosity 1p36 and 19q13 Is a Prognostic Factor for Overall Survival in Patients With Diffuse WHO Grade 2 Gliomas Treated Without Chemotherapy

Journal of Clinical Oncology ◽

10.1200/jco.2006.05.9238 ◽

2006 ◽

Vol 24 (29) ◽

pp. 4758-4763 ◽

Cited By ~ 60

Author(s):

Luigi Mariani ◽

Gianluca Deiana ◽

Erik Vassella ◽

Ali-Reza Fathi ◽

Christine Murtin ◽

...

Keyword(s):

Overall Survival ◽

Prognostic Factor ◽

Malignant Transformation ◽

Loss Of Heterozygosity ◽

Progression Free Survival ◽

Who Grade ◽

Free Survival ◽

Extent Of Surgery ◽

Oligodendroglial Component ◽

The Impact

Purpose This study was conducted to elucidate the impact of loss of heterozygosity (LOH) for chromosomes 1p36 and 19q13 on the overall survival of patients with diffusely infiltrating WHO grade 2 gliomas treated without chemotherapy. Patients and Methods We assessed the LOH status of tumors from patients harboring WHO grade 2 gliomas diagnosed between 1991 and 2000. Patients were either followed after initial biopsy or treated by surgery and/or radiation therapy (RT). Overall survival, time to malignant transformation, and progression-free survival were last updated as of March 2005. Results Of a total of 79 patients, LOH 1p36 and LOH 19q13 could be assessed in 67 and 66 patients, respectively. The median follow-up after diagnosis was 6 years. Loss of either 1p or 19q, in particular codeletion(s) at both loci, was found to positively impact on both overall survival (log-rank P < .01), progression-free survival, and survival without malignant transformation (P < .05). Tumor volume (P < .0001), neurologic deficits at diagnosis (P < .01), involvement of more than one lobe (P < .01), and absence of an oligodendroglial component (P < .05) were also predictors of shorter overall survival. The extent of surgery was similar in patients with or without LOH 1p and/or 19q; RT was more frequently resorted to for patients without than for patients with LOH 1p/19q (30% v 60%). Conclusion The presence of LOH on either 1p36 or 19q13, and in particular codeletion of both loci is a strong, nontreatment-related, prognostic factor for overall survival in patients with diffusely infiltrating WHO grade 2 gliomas.

Download Full-text

Canadian Retrospective Multicentric Study Comparing the Combination of Bortezomib, Cyclophosphamide and Dexamethasone (Cybord) Versus Bortezomib, Thalidomide and Dexamethasone (VTD) Versus Bortezomib and Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Hematopoietic Stem Cell Transplantation (HCT)

Blood ◽

10.1182/blood-2018-99-117571 ◽

2018 ◽

Vol 132 (Supplement 1) ◽

pp. 2010-2010

Author(s):

Eric Yamga ◽

Richard Leblanc ◽

Jean-Samuel Boudreault

Keyword(s):

Overall Survival ◽

Survival Rate ◽

Treatment Response ◽

Board Of Directors ◽

Response Rate ◽

Progression Free Survival ◽

Response Rates ◽

Advisory Committees ◽

Hematopoietic Stem ◽

Free Survival

Abstract Background: Multiple myeloma (MM) is the second most common hematologic cancer. The management of this disease consists of induction therapy followed by autologous hematopoietic stem cell transplantation (HCT). There is no standard of care as for the best induction regime. Recently, the first phase III study (Moreau P and all.) comparing two chemotherapy triplets in transplant-eligible patients, suggested a superiority of VTD over VCD. Although VTD was associated with better treatment response rates, the survival data remains to be seen. We wanted to retrospectively compare 3 Bortezomib-based therapies using response rates (RR), progression-free survival (PFS) and overall survival (OS). Bortezomib-Cyclophosphamide-Dexamethasone (CyBorD) remains the standard in Canada. Method: A total of 75 patients induced between 2010 and 2016 were analyzed. Their charts were reviewed and the data was retrospectively collected. Three distinct treatment groups were included : Vd (19), CyBorD (39) and VTD (17).The main outcome was treatment response rate, 2-year progression-free survival rate (PFS) and 2-year overall survival rate (OS). The secondary outcome was median PFS. Results: Patient characteristics are presented below (table 1). The difference between the treatment response rates were non-statistically significant but demonstrated a favorable trend towards VTD as the VGPR rate was 58.8%, 65% and 88.1% respectively in the Vd, CyBoRD and VTD groups (table 2 and 3). Median progression-free survival was significantly longer in the group that received VTD than in the group that received CyBord (3.58 years vs. 2,80 years; P = 0.03). The 2-year overall survival rate was 88,9%, 96,3% et 93,3% respectively in the 3 groups (table 4). Conclusion: The data from this retrospective study supports the superiority of the VTD induction regimen compared with CyBorD and Vd in terms of response rate and progression-free survival. However, there is no major difference in overall survival over the time period observed. Disclosures Leblanc: Amgen Canada: Membership on an entity's Board of Directors or advisory committees; Takeda Canada: Membership on an entity's Board of Directors or advisory committees; Celgene Canada: Membership on an entity's Board of Directors or advisory committees; Janssen Inc.: Membership on an entity's Board of Directors or advisory committees. Boudreault:Celgen: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees.

Download Full-text

Intraperitoneal therapy for ovarian cancer: Impact on survival and recurrence—The result of multi-institutional studies

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.16068 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 16068-16068

Author(s):

S. Takeuchi ◽

H. Tsubamoto ◽

S. Adachi ◽

K. Ito ◽

Y. Itani ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Survival Rate ◽

Response Rate ◽

Progression Free Survival ◽

Observation Time ◽

Free Survival ◽

Intraperitoneal Therapy ◽

Impact On Survival ◽

The Mean

16068 Background: For optimal debulked mullerian cancer (MC), the Intraperitoneal (IP) therapy has become the effective modality of chemotherapy to obtain better prognosis. We have reported KCOG9811study: IP CDDP + Paclitaxel (PTX) intravenous (IV) 2 cycles followed by 3 cycles of usual PTX-Carboplatin (abstr.1970, ASCO2002). And we have also reported the feasibility study and satisfactory response rate of the weekly IP-PTX with IV Carboplatin therapy (IP-PIVC, abstr. 5120, ASCO2005). Objectives: We have conducted two types of IP therapy for optimal debulked MC to improve the progression free survival (PFS) and overall survival (OS). Here are the prognosis and recurrent fashion after these IP therapies. Methods: Twenty patients (pts) with optimal debulked ovarian cancer were enrolled for KCOG9811, and eleven pts with optimal debulked MC newly/recurrent diagnosed disease were enrolled for IP-PIVC. The regimen of each therapy consisted of as follows: KCOG9811:50mg/ m2 of CDDP was administered via IP port at operation, after 2 weeks (wks) of operation, PTX was administered at a dose of 175mg/ m2IV for 3hrs on day 1, CDDP was administered at 75mg/ m2IP on day 2, every 3wks for 2 cycles, followed by PTX 175mg/ m2 IV and Carboplatin AUC5 IV on day1 every 3wks for 3 cycles. The IP-PIVC therapy consisted of IP-PTX, on days 1, 8, 15 at a dose of 45 mg/m2 (3pts) and 60 mg/m2(8pts). Carboplatin was administered monthly at a dose of AUC 5 on day 1 only. 2–6 cycles were performed. Results: The mean observation time was 72.6 months (m) and 32.6m for KCOG9811 and IP-PIVC, respectively. As for the median PFS was 1308+ days and 678+ days, and the median OS was 2180+ days and 978+ days, respectively. The five years survival rate showed 59.3% on KCOG9811, and the three years survival rate showed 75.8% on IP-PIVC. As for recurrent fashion, liver metastases and proximal lymphnodes metastases, and retroperitoneal metastases were detected. Few cases recurred Intraperitoneal lesion with small ascites Conclusions: There are some differences in the recurrent fashion of IP treatment from that of IV treatment. IP treatment prevented ascitic recurrence. Further improvement of chemotherapy is necessary for liver metastasis and proximal lymphnodes. [Table: see text]

Download Full-text

Everolimus treatment-associated interstitial lung disease (ILD) as a prognostic factor in Japanese patients with metastatic renal cell carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e15531 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e15531-e15531

Author(s):

Fumiya Hongo ◽

Masakatsu Oishi ◽

Takashi Ueda ◽

Yasunori Kimura ◽

Terukazu Nakamura ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Interstitial Lung Disease ◽

Prognostic Factor ◽

Adverse Events ◽

Cell Carcinoma ◽

Renal Cell ◽

Progression Free Survival ◽

Japanese Patients ◽

Free Survival

e15531 Background: Interstitial lung disease (ILD) is one of the adverse events during treatment with everolimus for metastatic renal cell carcinoma (mRCC). Japanese study of everolimus treatment-associated ILD as a prognostic factor is rare. Methods: We retrospectively assessed the incidence and outcome of ILD in mRCC patients treated with everolimus. Between April 2010 and August 2012, 25 cases were treated with everolimus after the failure of one or two TKIs in our institute. All adverse events were graded in accordance with NCI CTCAE, version 3.0. Results: A total of 25 patients received treatment with everolimus and included 18 male and 7 female patients ranging in age from 21 to 84 years (median 62). According to MSKCC risk criteria, 6 cases were at favorable risk, 16 cases were at intermediate risk, and 3 cases were at poor risk. The median treatment term was 4 months (range 2-17 months). SD was reported in 19 cases and PD in 6 cases. Progression free survival was 3.5 months and overall survival was 12 months. ILD was found in 7 cases (28%). One was G1, five were G2, and one was G3. Corticosteroid therapy was initiated in 3 cases. In 5 of 7 ILD cases, everolimus was re-challenged. In our series, patients with ILD showed significantly better progression free survival than those without ILD (PFS was 8 months vs 3 months. Log-rank, P<0.001). There were no significant differences between the two groups in overall survival (12 months in patients with ILD vs 10 months in patients without ILD. Log-rank, NS). Conclusions: Everolimus appears to have been effective and well-tolerated in our institute. Re-challenge with everolimus was feasible after improving everolimus-induced ILD in cases of grade 1-2. To confirm these findings, the efficacy and AE profile of everolimus in Japanese patients should be investigated.

Download Full-text

Efficacy and dosimetry prognostic factors of image guided 125I seed implantation for locally recurrent soft tissue sarcoma.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.11073 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. 11073-11073

Author(s):

Weijuan Jiang ◽

Ping Jiang ◽

Ang Qu ◽

Junjie Wang ◽

Haitao Sun

Keyword(s):

Overall Survival ◽

Survival Rate ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Survival Rates ◽

Progression Free Survival ◽

Ct Guided ◽

Free Survival ◽

Seed Implantation ◽

Local Progression

11073 Background: To observe the effect of ultrasound / CT guided radioactive 125I seed implantation in the treatment of recurrent soft tissue sarcoma and its relationship with physical dosimetry prognostic factors. Methods: The data of 37 patients with recurrent soft tissue sarcoma who received ultrasound/CT-guided 125I seed implantation from November 2005 to December 2015 were retrospectively analyzed. The local progression-free survival rate and overall survival rate were evaluated. The relationship of local progression-free survival rate and overall survival with physical dosimetric parameters was analyzed. Results: Thirty-seven patients, 20 males and 17 females, with a median age of 53 years (16-79 years), received a median radiation dose of 60 Gy (28 Gy-120 Gy). The median tumor volume was 46.8 cm3 (0.5-252.2 cm3), the median particle activity was 0.67 mCi (0.4-0.84 mCi), and the median implanted particle number was 60 (3-158). The median follow-up time was 20 months (range: 1~144 months). The median overall survival time was 20.0 months (95% CI 16.4-23.6 months). The overall survival rates of 1, 3 and 5 years were 62.2%, 34.3% and 27.7% respectively. The median local progression-free time was 63.0 months. The 1-year, 3-year and 5-year local progression-free survival rates were 68.9%, 55.0% and 47.1%, respectively. Correlation analysis showed that HI was positively correlated with total survival and local progression-free survival (P = 0.001). Multivariate analysis showed that HI ( > 0.25) was an independent prognostic factor for long overall survival (P = 0.048, HR 0.39), and D90 ( > 110 Gy) was an independent prognostic factor for long local progression-free survival (P = 0.024, HR 0.17). Conclusions: Ultrasound/CT guided 125I seed implantation is a safe and effective method for the treatment of recurrent soft tissue sarcoma with high local control rate. The HI and D90 of the postoperative plan maybe affect the therapeutic efficacy.

Download Full-text